Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Azstarys — Intangible Asset, Finite-Lived, after Accumulated Amortization

Other product segments

Jornay PM
$482.01M-14.8%
Symproic and other
$42.5M-14.6%
Symproic
$38.86M-15.8%
Belbuca
$37.7M-66.7%

Similar metrics at other companies

Acacia Research logo
ACTGIndustrial operations — Intangible Asset, Finite-Lived, after Accumulated Amortization
$1.72M-30.6%
Acacia Research logo
ACTGManufacturing Operations — Intangible Asset, Finite-Lived, after Accumulated Amortization
$19.34M-9.7%
Acacia Research logo
ACTGIntellectual property operations — Intangible Asset, Finite-Lived, after Accumulated Amortization
$10.22M-57.9%
Viatris logo
VTRSBrands — Finite-lived intangible assets, net
$13.11B-10.7%
Viatris logo
VTRSGenerics — Finite-lived intangible assets, net
$1.29B-18.0%
Mannkind logo
MNKDISPERSE License — Finite Lived Intangible Assets Net
$4.3M

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemJune 30, 2026 / CostJune 30, 2026 / Accumulated AmortizationJune 30, 2026 / Carrying AmountDecember 31, 2025 / CostDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Carrying Amount
Jornay PM$635,000$(152,986)$482,014$635,000$(111,072)$523,928
Azstarys635,000(7,480)627,520
Belbuca360,000(322,305)37,695360,000(284,607)75,393
Nucynta Products521,170(521,170)521,170(493,478)27,692
Symproic70,000(31,145)38,85570,000(27,503)42,497
Total intangible assets$2,221,170$(1,035,086)$1,186,084$1,586,170$(916,660)$669,510

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s azstarys — intangible asset, finite-lived, after accumulated amortization?
Collegium Pharmaceutical, Inc. (COLL) reported azstarys — intangible asset, finite-lived, after accumulated amortization of $627.52M in Q2 2026.
What does azstarys — intangible asset, finite-lived, after accumulated amortization mean?
Represents the current net book value of the Azstarys intangible asset after deducting accumulated amortization. It provides insight into the remaining value of the asset on the balance sheet and its potential for future economic benefit.

Ask your AI about Collegium Pharmaceutical, Inc.'s azstarys — intangible asset, finite-lived, after accumulated amortization.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude